Account
Insider Insights
28.07.2022
Federal cabinet approves Lauterbachs draft GKV

One notable change from the last released updated bill was the removal of the solidarity levy of 2 b...

Read more
News
29.06.2022
PMA Insights: Week 26

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
09.06.2022
What is the New Innovative Medicines Fund and What...

The Innovative Medicines Fund launched on 7th June 2022 The Innovative Medicines Fund (IMF), which w...

Read more
Insider Insights
09.06.2022
UK launch of innovative medicines fund

Through the new fund, £340 million is to be made available to purchase promising, potentially life-...

Read more
Insider Insights
24.05.2022
Preliminary analysis of reformed early access

The High Authority for Health (HAS) and National Agency for Drug Safety (ANSM) have published a prel...

Read more
Insider Insights
20.05.2022
Improving market access for new drugs

With respects to pricing and reimbursement, the societies reportedly call for the criteria that led ...

Read more
Insider Insights
19.05.2022
AstraZenecas Imfinzi approved for routine NHS use

Durvalumab was previously made available to NHS patients in 2019 through the Cancer Drugs Fund (CDF)...

Read more
Insider Insights
04.05.2022
CNAM spending on medicines 11.1% in 2022

Spending by the main health insurance fund (Caisse nationale d’assurance maladie, CNAM) on medicin...

Read more
Insider Insights
29.04.2022
EUCOPE anticipates OMP Regulation review

EUCOPE notes that “while these proposals don’t necessarily represent the final options included ...

Read more
Insider Insights
20.04.2022
Access to cancer drugs

According to the report, the financing of cancer drugs in Spain is “very high” with 90% of oncol...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.